Novartis has announced that its CGRP inhibitor Aimovig (erenumab-aooe) can reduce monthly migraine days by about half.
Data from the STRIVE Phase III trial showed that 55% of patients on Aimovig 140mg experienced at least a 50% reduction in the number of monthly migraine days requiring acute medication at week 52.
It also demonstrated sustained efficacy of Aimovig through week 52 in episodic migraine patients who failed prior preventive treatments; reinforcing Novartis’ commitment to reimagine medicine for patients across the spectrum of migraine
In addition to the STRIVE data, Aimovig was recently found to reduce monthly migraine days at 13 to 24 weeks in episodic migraine patients with two to four prior preventive treatment failures in the LIBERTY Phase IIIb study.
The new sets of data “underline the long-term efficacy of Aimovig for patients who have struggled to find effective preventive therapies specifically designed for migraine,” said Danny Bar-Zohar, global head, Neuroscience Development for Novartis Pharmaceuticals.
Danny continued, “Being able to propose additional solutions, such as Aimovig, for patients with prior preventive treatment failures is key to help them get their lives back.”
The additional long-term data in a population with prior treatment failures complement Aimovig’s position as the most prescribed anti CGRP, with more than 220,000 patients prescribed worldwide since its launch.
The STRIVE data will be presented at the European Academy of Neurology (EAN) annual meeting in Oslo, Norway.
